Ask AI
ProCE Banner Activity

CE / CME

Combating Myeloma: Improving Access and Outcomes With CAR T-Cell and Bispecific Antibody Therapies in Veterans With Relapsed/Refractory Multiple Myeloma

Video

In this certified on-demand webcast, an expert discusses how immunotherapies, including BCMA- and GPRC5D-targeted CAR T-cell therapies, bispecific antibodies, and antibody–drug conjugates, are reshaping treatment sequencing for relapsed/refractory multiple myeloma while highlighting practical considerations such as bridging strategies, toxicity management, and infection prophylaxis.

Nurse Practitioners/Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: January 12, 2026

Expiration: July 11, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Bristol Myers Squibb and Johnson & Johnson.

Bristol Myers Squibb

Johnson & Johnson

Target Audience

This activity is intended for hematologists, oncologists, nurses, physician associates, pharmacists, and other healthcare professionals in VA medical centers caring for patients with relapsed/refractory multiple myeloma.

Program Learning Goal

This activity aims to improve learners’ knowledge, competence, and performance in integrating CAR T-cell and bispecific antibody therapies into practice to improve clinical outcomes in patients with relapsed/refractory multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the eligibility of patients with relapsed/refractory MM for CAR T-cell therapy based on patient and disease characteristics, current indications, and expert recommendations

  • Identify patients with relapsed/refractory MM planned for CAR T-cell therapy who are likely to benefit from salvage and/or bridging therapy

  • Develop individualized treatment strategies leveraging CAR T-cell or bispecific antibody therapies for patients with relapsed/refractory MM after at least 1 prior line of therapy based on clinical data, approvals, expert recommendations, and patient factors

  • Implement strategies supporting equitable access to novel therapies and clinical trials in Black and underserved populations with relapsed/refractory MM

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Carol Ann Huff, MD: consultant/advisor/speaker: Johnson & Johnson, Prothena, Sanofi; researcher: Johnson & Johnson, Prothena.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below:​

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, DSI, Exelixis, Lilly, Pfizer, Stemline.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 12, 2026, through July 11, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacotherapy credit.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: xxxx

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days

Physician Associate Continuing Medical Education

AAPA CME Accreditation - AAPA

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until July 11, 2026. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

  • Care Continuum (OCN, CBCN, AOCNP) - 1.0*
  • Oncology Nursing Practice (OCN) - 1.0*
  • Psychosocial Dimensions of Care (AOCNP, CPHON, OCN, CBCN) - 0.2*
  • Roles of the APRN (AOCNP) - 0.5*
  • Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP) -1.0*
  • Treatment (OCN, CBCN, AOCNP, CPHON) - 1.0*

Total Points: 1.0*

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of ILNA points claimed may not exceed the total amount of nursing continuing professional development (NCPD) awarded from this course.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.